Zobrazeno 1 - 10
of 40
pro vyhledávání: '"Chongfeng Xu"'
Publikováno v:
Frontiers in Immunology, Vol 9 (2018)
RIG-I signaling is critical to host innate immune response against RNA virus infection, and also can be activated against many kinds of cancer. Oncogene LMP1 of Epstein–Barr virus (EBV) contributes to various tumors progress. In this study, we have
Externí odkaz:
https://doaj.org/article/913a67c8e1e5411eb0553364871e8019
Autor:
Chongfeng Xu, Ziyuan Duan
Publikováno v:
Protein & Cell, Vol 8, Iss 1, Pp 1-3 (2016)
Externí odkaz:
https://doaj.org/article/c731c2b806764f9088e49d11b94cdcf1
Autor:
Wei Liu, Jing Li, Weinan Zheng, Yingli Shang, Zhendong Zhao, Shanshan Wang, Yuhai Bi, Shuang Zhang, Chongfeng Xu, Ziyuan Duan, Lianfeng Zhang, Yue L Wang, Zhengfan Jiang, Wenjun Liu, Lei Sun
Publikováno v:
eLife, Vol 6 (2017)
RIG-I is a key cytosolic pattern recognition receptor that interacts with MAVS to induce type I interferons (IFNs) against RNA virus infection. In this study, we found that cyclophilin A (CypA), a peptidyl-prolyl cis/trans isomerase, functioned as a
Externí odkaz:
https://doaj.org/article/6555b1c46ad8457eb97313f044b02231
Publikováno v:
PLoS ONE, Vol 7, Iss 2, p e31063 (2012)
Cyclophilin A (CypA) is a typical member of the cyclophilin family of peptidyl-prolyl isomerases and is involved in the replication of several viruses. Previous studies indicate that CypA interacts with influenza virus M1 protein and impairs the earl
Externí odkaz:
https://doaj.org/article/9cb9177f734e4f3d8574d2ff71a96a5b
Publikováno v:
PLoS ONE, Vol 7, Iss 5, p e37277 (2012)
The immunosuppressive drug cyclosporin A (CsA) has inhibitory effects on the replication of several viruses. The antiviral effects are through targeting the interaction between viral proteins and host factor cyclophilin A (CypA). CypA has been identi
Externí odkaz:
https://doaj.org/article/bd492e7179a143f08bb0476e97a69f86
Autor:
Zengfu Wang, Xiaoling Liu, Zhendong Zhao, Chongfeng Xu, Ke Zhang, Caiwei Chen, Lei Sun, George F Gao, Xin Ye, Wenjun Liu
Publikováno v:
PLoS ONE, Vol 6, Iss 8, p e22625 (2011)
BackgroundThe nucleoprotein (NP) of influenza A virus is a multifunctional protein that plays a critical role in the replication and transcription of the viral genome. Therefore, examining host factors that interact with NP may shed light on the mech
Externí odkaz:
https://doaj.org/article/5b052dc924e54ad580b675f6edbe0ffe
Autor:
Christina S. Alves, Chongfeng Xu, Yizhou Zhou, Baohong Zhang, Justin Crisafulli, Eric Marshall, Patrick Cullen, Fergal Casey, Thomas M. Carlile, Chao Sun, Dongdong Lin, Joost Groot
Publikováno v:
Biotechnology journalREFERENCES. 16(8)
In recent years High-Throughput Sequencing (HTS) based methods to detect mutations in biotherapeutic transgene products have become a key quality step deployed during the development of manufacturing cell line clones. Previously we reported on a high
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c7ec4f571cfa5cc295a3e29b246dc19
https://pubmed.ncbi.nlm.nih.gov/34018310
https://pubmed.ncbi.nlm.nih.gov/34018310
Autor:
Chao Sun, Justin Crisafulli, Dongdong Lin, Baohong Zhang, Yizhou Zhou, Patrick Cullen, Eric Marshall, Joost Groot, Thomas M. Carlile, Christina S. Alves, Fergal Casey, Chongfeng Xu
In recent years Next-Generation Sequencing (NGS) based methods to detect mutations in biotherapeutic transgene products have become a key quality step deployed during the development of manufacturing cell line clones. Previously we reported on a high
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::673eb23f17e8240401d01b49c93bb93b
https://doi.org/10.22541/au.160397369.95796795/v1
https://doi.org/10.22541/au.160397369.95796795/v1
Autor:
Adriana Bajardi-Taccioli, Tim Brantley, Marina Feschenko, Christine Bond, Allyson Masci, Chongfeng Xu, Svetlana Bergelson, Carl Co
Publikováno v:
Analytical biochemistry. 611
FcγRIIa receptor binding is part of the mechanism of action for many therapeutic antibodies. AlphaScreen® technology and Biolayer Interferometry (BLI) are often used to assess protein-protein interactions. Recently we demonstrated that the presence
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::95eed7a6ffabf7ce4cd4e9c467710fd7
https://pubmed.ncbi.nlm.nih.gov/32755599
https://pubmed.ncbi.nlm.nih.gov/32755599
Autor:
Mei Liu, Samantha Swahn, Helen McLaughlin, Chapman Wright, Scott Estes, Chongfeng Xu, Joost Groot, Chao Sun, Eric Zheng
Publikováno v:
Biotechnology Progress. 32:813-817
A central goal for most biopharmaceutical companies is to reduce the development timeline to reach clinical proof of concept. This objective requires the development of tools that ensure the quality of biotherapeutic material destined for the clinic.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d6828943d6d0b40e6e897e86371b14b
https://doi.org/10.1002/btpr.2263
https://doi.org/10.1002/btpr.2263